Biblio Discovery — Demo Discovery Service

7 hasil untuk "Richard Nicholas"

Menampilkan 1–7 · 0,29 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Progressive Dwindling in Multiple Sclerosis: An Opportunity to Improve Care

    Jessica E. Martin; Joel Raffel; Richard Nicholas

    PLOS ONE, Vol. 11 No. 7 · 2016 · Inggris · PLOS Scopus

    Introduction: In the general ageing population, 40% of deaths occur following a prolonged trajectory of “progressive dwindling,” characterised by chronic accumulation of disability and frailty, and associated with increased dependency and reduced reserves. Those who progressively dwindle are poorly…

  2. Artikel Jurnal Teks lengkap

    Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression

    Christian Röver; Richard Nicholas; Sebastian Straube dkk.

    PLOS ONE, Vol. 10 No. 9 · 2015 · Inggris · PLOS Scopus

    Background: Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS) revealed a decrease in placebo annualized relapse rates (ARR) over the past two decades. Furthermore, regression to the mean effects were observed in ARR and MRI lesion counts. It is…

  3. Artikel Jurnal Teks lengkap

    Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale–29

    Joel Raffel; Alison Wallace; Djordje Gveric dkk.

    PLOS Medicine, Vol. 14 No. 7 · 2017 · Inggris · PLOS Scopus

    Background: There is increasing emphasis on using patient-reported outcomes (PROs) to complement traditional clinical outcomes in medical research, including in multiple sclerosis (MS). Research, particularly in oncology and heart failure, has shown that PROs can be prognostic of hard clinical…

  4. Artikel Jurnal Teks lengkap

    Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis

    Joel Raffel; Arie R. Gafson; Samer Dahdaleh dkk.

    PLOS ONE, Vol. 12 No. 1 · 2017 · Inggris · PLOS Scopus

    Background: In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, new MRI lesions and relapses during the first year of treatment predict a poor prognosis. Objective: To study this association in those receiving natalizumab. Methods: Data were collected on relapses…

  5. Artikel Jurnal Teks lengkap

    Peripheral Nerve Dysfunction in Middle-Aged Subjects Born with Thalidomide Embryopathy

    Alessia Nicotra; Claus Newman; Martin Johnson dkk.

    PLOS ONE, Vol. 11 No. 4 · 2016 · Inggris · PLOS Scopus

    Background: Phocomelia is an extremely rare congenital malformation that emerged as one extreme of a range of defects resulting from in utero exposure to thalidomide. Individuals with thalidomide embryopathy (TE) have reported developing symptoms suggestive of peripheral nervous system dysfunction…

  6. Artikel Jurnal Teks lengkap

    A realist review of advance care planning for people with multiple sclerosis and their families

    Laura Cottrell; Guillaume Economos; Catherine Evans dkk.

    PLOS ONE, Vol. 15 No. 10 · 2020 · Inggris · PLOS Scopus

    Background: Advance care planning (ACP) is reported to improve the quality of outcomes of care among those with life-limiting conditions. However, uptake is low among people living with multiple sclerosis (MS) and little is known about why or how people with MS engage in this process of…

  7. Artikel Jurnal Teks lengkap

    “I wanna live and not think about the future” what place for advance care planning for people living with severe multiple sclerosis and their families? A qualitative study

    Jonathan Koffman; Clarissa Penfold; Laura Cottrell dkk.

    PLOS ONE, Vol. 17 No. 5 · 2022 · Inggris · PLOS Scopus

    Background: Little is known about how people with multiple sclerosis (MS) and their families comprehend advance care planning (ACP) and its relevance in their lives. Aim: To explore under what situations, with whom, how, and why do people with MS and their families engage in ACP. Methods: We…